Research programme: bispecific antibody therapeutics - Amgen/MD Anderson Cancer Center

Drug Profile

Research programme: bispecific antibody therapeutics - Amgen/MD Anderson Cancer Center

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; CD3 antigen inhibitors; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Small cell lung cancer

Most Recent Events

  • 31 May 2018 Amgen and the University of Texas MD Anderson Cancer Center collaborates to develop bispecific antibodies in USA for Leukaemia, Multiple myeloma, Small cell lung cancer, Myelodysplastic syndromes and Cancer
  • 31 May 2018 Preclinical trials in Leukaemia in USA (Parenteral)
  • 31 May 2018 Preclinical trials in Multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top